ClinicalTrials.gg
CompletedNCT05071703Updated Oct 6, 2023

Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study

A Phase 4 interventional study of Trilaciclib in Extensive-stage Small-cell Lung Cancer, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2022, 4 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Enrollment
270th of 333
30 · median 63
Started
2021
with 31 others
Phase 4
7 of 365
5 open now
Registered
140th of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 270th largest by enrollment of the 333 interventional ones that give a count, is one of 32 that started in 2021, is one of 7 in phase 4, and was the 140th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, real-world study in Chinese patients with extensive stage small cell lung cancer. The purpose of this study was to evaluate Trilaciclib's protection against chemotherapy-induced bone marrow suppression, the safety and the impact on the antitumor effects of the combination with chemotherapy in Chinese patients with ES-SCLC in the real world. Patients with ES-SCLC who already use or plan to use Trilaciclib will be invited to participate in the study. Data were collected from 28 days prior to initial chemotherapy (platinum/etoposide or topotecan systemic chemotherapy) after patients signed informed consent until patients died, dropped out of the study, lost to follow-up, informed withdrawal, or study termination. The end time of the study was defined as withdrawal of information, loss of follow-up or death of all enrolled patients, or 12 months after the last patient was enrolled, whichever happened earlier.

03

Conditions studied

  • Extensive-stage Small-cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate and sign ;
  2. must be at least 18 years when fisrt dose of Trilaciclib, regardless of gender:
  3. Patients with extensive small-cell lung cancer confirmed by histology or cytology
  4. Patients suitable for Trilaciclib combined with platinum/etoposide or Trilaciclib combined with topotecan treatment

Exclusion criteria

Exclusion Criteria:

  1. Patient is currently participating in other Interventional clinical studies;
  2. Patients received systemic chemotherapy other than the regimens recommended in inclusion criteria 4 During Trilaciclib treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Trilaciclib, carboplatin, etoposide, Topotecan

    Trilaciclib plus Carboplatin combined with Etoposide OR Topotecan (ES-SCLC patients)

    Drug: Trilaciclib

Interventions

  • * Carboplatin combined with Etoposide (ES-SCLC patients) * plus Topotecan (second/third line ES-SCLC patients)

    Also known as: Trilaciclib, carboplatin, etoposide#or Topotecan

06

What researchers measure

Primary outcomes

  1. Incidence of severe neutropenia (SN)

    Incidence of severe neutropenia (SN)

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

Secondary outcomes

  1. Incidence of grade 3 and 4 hematologic toxicity

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  2. Incidence of intravenous or oral antibiotic administration in treatment

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  3. Incidence of G-CSF treatment

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  4. Changes of absolute neutrophil count, platelet count, absolute lymphocyte count (ALC) and hemoglobin over time

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  5. Incidence of red blood cell (RBC) transfusions at or after week 5

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  6. The incidence of ESA administration in treatment

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  7. The incidence of TPO administration in treatment

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  8. The incidence of platelet transfusion

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  9. The number and frequency of all-caused chemotherapy drugs reduction

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  10. composite end point - Significant hematologic adverse event (occurrence of any of the following events:all-cause hospitalization; all-cause dose reduction; Febrile neutropenia; Severe neutropenia )

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  11. Incidence of infectious serious adverse events

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  12. Incidence of pulmonary infection serious adverse events

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  13. The incidence of febrile neutropenia

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  14. Objective response rate

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  15. duration of response

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  16. Progression-free survival time

    Time frame: during Trilaciclib plus chemotherapy assessed up to 6 months

  17. Disease control rate

    Time frame: during chemotherapy assessed up to 6 months

  18. verall survival

    Time frame: maximun up to 1.5 years

07

Study locations

1 site
  • Hainan General Hospital
    Haikou, Hainan 100021, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Apr 2022, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2021
First posted
Oct 8, 2021
StartActual
Aug 11, 2021
Primary completionActual
Apr 10, 2022
CompletionActual
Nov 30, 2022
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05071703
Responsible party
Sponsor
First posted
Oct 8, 2021
Start date
Aug 11, 2021
Primary completion
Apr 10, 2022
Completion
Nov 30, 2022
Last update
Oct 6, 2023

Study contacts

Yongxing Chen
principal investigator · Hainan General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trilaciclib

Start the discussion